2014 News Releases
Researchers target the cell’s ‘biological clock’ in promising new therapy to kill cancer cells, shrink tumor growth
Cell biologists at UT Southwestern Medical Center have targeted telomeres with a small molecule called 6-thiodG that takes advantage of the cell’s ‘biological clock’ to kill cancer cells and shrink tumor growth.
Stereotactic body radiation therapy plus chemotherapy improves survival among stage 4 lung cancer patients
A clinical trial that combined stereotactic body radiation therapy with a specific chemotherapy regimen more than doubled survival rates for certain stage 4 lung cancer patients
UT Southwestern Medical Center cancer researchers have demonstrated that whole-genome sequencing can be used to identify patients’ risk for hereditary cancer.
National trial first to focus on long-term complications associated with chronic kidney disease, diabetes, hypertension
UT Southwestern will lead the first National Institutes of Health-funded, multicenter, clinical trial to address interventions for patients with multiple chronic conditions centered around kidney disease.
Researchers at UT Southwestern and Karolinska Institutet in Stockholm, Sweden, found that endogenous retroviruses (ERV) play a critical role in the body’s immune defense against common bacterial and viral pathogens.
UT Southwestern Medical Center researchers have discovered that brain tumors are capable of burning acetate for fuel, providing a new potential target for halting tumor growth.
A “real-time” radiation monitor that alerts by beeping in response to radiation exposure during cardiac-catheterization procedures significantly reduces the amount of exposure that medical workers receive, UT Southwestern Medical Center researchers fo
UT Southwestern Medical Center researchers have identified a possible therapy to treat neurofibromatosis type 1 or NF1.
UT Southwestern Medical Center neurology researchers have identified an important cell signaling mechanism that plays an important role in brain cancer and may provide a new therapeutic target.
Approximately 200 patients safely moved to innovative facility, marking new era in clinical care.